Even though there are limited trials evaluating the use of G-CSF for drug-induced neutropenia, G-CSF may be considered in high-risk patients including those with ANCs of less than 100 cells/mm3 due to increased risk of mortality in these patients [33, 39]. The gene discussed is CSF3; the disease is Decreased total neutrophil count.